Octapharma USA sponsored the National Hemophilia Foundation’s (NHF) 71st Bleeding Disorders Conference and introduced two new clinical trials focused on von Willebrand Disease (VWD). The clinical trials were featured in poster presentations at the NHF meeting held in Anaheim, California last week.
The first study is expected to determine the efficacy and safety of WILATE ® during prophylaxis in previously treated patients with VWD, specifically patients with type 3, type 2 (except 2N), or severe type 1 VWD.
Affecting approximately 1 percent of the population, VWD is a common inherited bleeding disorder that occurs when the blood lacks a protein that helps clotting. Type 3 VWD is the rarest and most severe form of the condition, representing approximately 5% of cases, according to the National Organization for Rare Disorders.
Octapharma USA President Flemming Nielsen stated that “This study is intended to provide data on the efficacy of prophylactic treatment in reducing the rate of bleeding and on the impact of prophylaxis on the quality of life in VWD patients.”
The second clinical trial, von Willebrand Factor in Pregnancy (VIP...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).